<scp>Type 2 diabetes</scp> subgroups and response to glucose‐lowering therapy: Results from the <scp>EDICT</scp> and Qatar studies-Reference-Cited by-同舟云学术

Type 2 diabetes subgroups and response to glucose‐lowering therapy: Results from the EDICT and Qatar studies

Published:2022-06-29 Issue:9 Volume:24 Page:1810-1818
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Abdul‐Ghani Tamam¹,Puckett Curtiss¹,Migahid Osama²,Abdelgani Siham¹,Migahed Ayman²,Adams John¹,Triplitt Curtis¹,DeFronzo Ralph¹^ORCID,Jayyousi Amin²,Abdul‐Ghani Muhammad¹^ORCID

Affiliation:

1. Division of Diabetes University of Texas Health Science Center and Texas Diabetes Institute San Antonio Texas USA

2. Hamad General Hospital Doha Qatar

Funder

National Institutes of Health

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14767

Reference23 articles.

1. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

2. Pathogenesis of Insulin Resistance in Skeletal Muscle

3. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables

4. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study

5. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis;Diabetes Therapy;2024-06-15

2. Etiologies underlying subtypes of long-standing type 2 diabetes;PLOS ONE;2024-05-28

3. Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial;Diabetes, Obesity and Metabolism;2023-10-20

4. Pharmacometabolomic Approach to Investigate the Response to Metformin in Patients with Type 2 Diabetes: A Cross-Sectional Study;Biomedicines;2023-08-01

5. Response to insulin glargine 100 U/mL treatment in newly-defined subgroups of type 2 diabetes: Post hoc pooled analysis of insulin-naïve participants from nine randomised clinical trials;Primary Care Diabetes;2023-08